- Cat. No.
- A13834
Linaclotide
Linaclotide is a peptide agonist of the guanylate cyclase 2C.
Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Guanylate cyclase stimulators and activators act on the enzymes that make the second messenger cGMP. These enzymes convert guanosine triphosphate into cyclic guanosine monophosphate (cGMP). Soluble guanylate cyclase (sGC) is the main receptor for nitric oxide (NO), whereas membrane-bound guanylate cyclase C (GC-C) binds peptide ligands. In 1990 GC-C was identified as the receptor for the heat-stable enterotoxin of Escherichia coli. BAY 41-2272 was described in 2001 as acting on an NO-independent regulatory site of sGC. Riociguat, vericiguat and praliciguat are further sGC stimulators, and YC-1 is an earlier sGC activator. Linaclotide is a peptide GC-C agonist used in studies of intestinal fluid secretion.
Linaclotide is a peptide agonist of the guanylate cyclase 2C.
Synonyms: BAY 63-2521
Riociguat (BAY 63-2521; BAY 632521) is a stimulator of soluble guanylate cyclase (sGC).
Synonyms: Lificiguat
YC-1 is a direct activator of soluble Guanylyl Cyclase (sGC), independent of Nitric Oxide.
Synonyms: BM121307
(4-Acetamidocyclohexyl) nitrate (BM121307) is a guanylate cyclase activator that was in phase I development for the treatment of ischaemic heart disorders. The research has been discontinued.
Synonyms: IW-1701
Olinciguat (IW-1701) is an oral guanylate cyclase (sGC) stimulator with concentration-dependent stimulation of sGC in purified rat and human enzyme assays and a whole cell assay.
BAY 41-2272 is a direct and NO-independent soluble guanylate cyclase (sGC) stimulator.
Synonyms: IW-1973
Praliciguat (IW-1973) is a potent and orally active soluble guanylate cyclase stimulator, enhances NO signaling, acts as a vasodilator. Praliciguat (IW-1973) stimulates sGC in HEK-293 cells with an EC50 of 197 nM.
Runcaciguat is an orally active stimulator of soluble guanylate cyclase, and is used in the research of cardiovascular and renal diseases combined with selective partial adenosine A1 receptor agonists.
Synonyms: BAY60-4552
Nelociguat (BAY60-4552) is a nitric oxide sensitive soluble guanylate cyclase stimulator.
Synonyms: BAY1021189
Vericiguat (BAY1021189) is a potent, orally available and soluble guanylate cyclase stimulator.
Cinaciguat is an activator of guanylate cyclase (sGC), and used for acute decompensated heart failure.
Plecanatide acetate is a guanylate cyclase-C (GC-C) receptor agonist, with an EC50 of 190 nM in T84 cells. Plecanatide acetate shows anti-inflammatory activity in models of murine colitis.
NS-2028 is a highly selective soluble Guanylyl Cyclase (sGC) inhibitor with IC50 values of 30 nM and 200 nM for basal and NO-stimulated enzyme activity.
Synonyms: BAY 58-2667 hydrochloride; BAY-58-2667
Cinaciguat hydrochloride is a potent soluble guanylate cyclase (GC) activator with EC50 of 15 nM in platelets.
ODQ is a potent and selective soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme) inhibitor. ODQ enhances the pro-apoptotic effects of Cisplatin in human mesothelioma cells.
MM 419447, a linaclotide metabolite, is a guanylate cyclase-C agonist. MM 419447 has the potential for the research of the irritable bowel syndrome with constipation (IBS-C).
Synonyms: CY-6463; IW-6463
Zagociguat is a soluble guanylate cyclase (sGC) stimulator that is orally active and penetrates the blood-brain barrier. This compound enhances intracellular levels of cGMP, leading to regulation of blood pressure, improved neuronal function, reduced inflammatory responses, and neuroprotective effects. Zagociguat is primarily utilized in research focused on neurodegenerative diseases.
BAY 60-2770 is a selective and orally active soluble guanylyl cyclase (sGC) activator that enhances sGC activity independent of nitric oxide. This compound exhibits significant antifibrotic properties, making it a valuable tool for research into fibrosis and related diseases. Its unique mechanism of action allows for exploration in various biological pathways associated with cardiovascular and respiratory health.
Plecanatide is a guanylate cyclase-C (GC-C) receptor agonist, functioning as an analogue of Uroguanylin. It effectively activates GC-C receptors, leading to the stimulation of cGMP synthesis, with an EC50 of 190 nM in T84 cell assays. Additionally, Plecanatide demonstrates anti-inflammatory activity in murine colitis models, making it useful for research into gastrointestinal disorders and related inflammatory conditions.
LY83583 is a selective inhibitor of soluble guanylate cyclase (sGC), effectively modulating the cGMP signaling pathway. This compound demonstrates significant biological activity by inhibiting kinase activity associated with tumor cell proliferation, particularly through the induction of the Cdk inhibitor p21. LY83583 is applicable for research in various cancer types, including colorectal cancer, breast cancer, and melanoma, as well as in studies related to cardiovascular disease.
Synonyms: HMR-1766
Ataciguat is a soluble guanylate cyclase (sGC) activator that functions independently of nitric oxide. It specifically activates the ferric heme-iron redox form of sGC, leading to increased production of cyclic GMP (cGMP). This compound demonstrates significant vasodilatory effects and is useful in research applications related to cardiovascular function and regulation of vascular tone.
Dolcanatide is an orally active agonist of guanylate cyclase-C (GC-C). This compound exhibits laxative, anti-nociceptive, and anti-inflammatory properties, making it suitable for various experimental applications. Dolcanatide is particularly relevant in research focused on inflammatory bowel disease.
MCUF-651 is a positive allosteric modulator of the guanylyl cyclase A receptor (GC-A), exhibiting a binding affinity (KD) of 397 nM. This compound selectively enhances the interaction of atrial natriuretic peptide (ANP) with GC-A, leading to increased cGMP production in human cardiac, renal, and adipose tissues. Additionally, MCUF-651 demonstrates the ability to inhibit cardiomyocyte hypertrophy, making it a valuable tool for research in cardiovascular and metabolic pathways.
Cenderitide is a potent agonist of particulate guanylyl cyclase receptors (pGC). This natriuretic peptide, composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP), activates pGC-A and pGC-B, leading to increased levels of the second messenger cGMP. Cenderitide effectively suppresses aldosterone production and helps preserve glomerular filtration rate (GFR) without causing a reduction in blood pressure. It is suitable for research applications focused on heart failure.
Linaclotide acetate is a potent and selective agonist of guanylate cyclase C, primarily involved in the regulation of intestinal fluid secretion. This compound enhances chloride and bicarbonate secretion, promoting gastrointestinal fluid accumulation and facilitating movement within the intestines. Linaclotide acetate is commonly utilized in research focused on gastrointestinal disorders, specifically for studying mechanisms and treatments related to constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.